Clinical Trials

    Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy

    Investigator: Eleni Efstathiou

    Study Coordinator:

    Status: Open Not Enrolling

    ClinicalTrials.gov Number: NCT03547973

    Phone:

    Protocol Number: Pro00021842

    Description


    This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 /PD-L1 based immunotherapy. At least 140 patients are anticipated to be enrolled across approximately 70 sites from North America, Europe and Asia. UNDER TEMPORARY HOLD FROM SPONSOR DUE TO COVID19